These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Vitamin D analogs: perspectives for treatment. Brown AJ; Slatopolsky E Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662 [TBL] [Abstract][Full Text] [Related]
46. Surgical treatment of the parathyroid gland in patients with end-stage renal disease. Albertucci M; Zielinski CM; Rothberg M; Sterpetti A; Klingman R; Ronk JF Surg Gynecol Obstet; 1988 Jul; 167(1):49-52. PubMed ID: 3381185 [TBL] [Abstract][Full Text] [Related]
47. [Treatment of secondary hyperparathyroidism in dialysis patients]. Di Luca M G Ital Nefrol; 2009; 26 Suppl 49():S36-48. PubMed ID: 19941277 [TBL] [Abstract][Full Text] [Related]
48. A new experimental model for secondary hyperparathyroidism. Sancho JJ; Duh QY; Oms L; Sitges-Serra A; Hammond ME; Arnaud CD; Clark OH Surgery; 1989 Dec; 106(6):1002-8. PubMed ID: 2588105 [TBL] [Abstract][Full Text] [Related]
49. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Mak RH; Turner C; Thompson T; Powell H; Haycock GB; Chantler C Br Med J (Clin Res Ed); 1985 Sep; 291(6496):623-7. PubMed ID: 3928054 [TBL] [Abstract][Full Text] [Related]
50. Vitamin D and its analogs in chronic renal failure. Slatopolsky E; Brown AJ Osteoporos Int; 1997; 7 Suppl 3():S202-8. PubMed ID: 9536333 [No Abstract] [Full Text] [Related]
51. Medical treatment in primary and secondary hyperparathyroidism. Coburn JW; Brickman AS; Massry SG Semin Drug Treat; 1972; 2(1):117-35. PubMed ID: 4261783 [No Abstract] [Full Text] [Related]
53. Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies. Muirhead N; Catto GR; Edward N; Adami S; Manning RM; O'Riordan JL Br Med J (Clin Res Ed); 1984 Jan; 288(6412):177-9. PubMed ID: 6419845 [TBL] [Abstract][Full Text] [Related]
54. Is control of secondary hyperparathyroidism optimal with the currently used calcium concentration in the CAPD fluid? Weinreich T; Rambausek M; Ritz E Nephrol Dial Transplant; 1991; 6(11):843-5. PubMed ID: 1775248 [TBL] [Abstract][Full Text] [Related]
55. Are we mismanaging calcium and phosphate metabolism in renal failure? Hsu CH Am J Kidney Dis; 1997 Apr; 29(4):641-9. PubMed ID: 9100059 [TBL] [Abstract][Full Text] [Related]
56. [New insights in the pathogenesis of secondary hyperparathyroidism]. Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Bellasi A; Galassi A; Gallieni M; Brancaccio D G Ital Nefrol; 2005; 22(4):329-36. PubMed ID: 16267793 [TBL] [Abstract][Full Text] [Related]
57. Calcium, phosphorus and vitamin D disorders in uremia. Slatopolsky E; Brown A; Dusso A Contrib Nephrol; 2005; 149():261-271. PubMed ID: 15876849 [TBL] [Abstract][Full Text] [Related]
58. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. Lee WT; Padayachi K; Collins JF; Cundy T J Am Soc Nephrol; 1994 Dec; 5(6):1344-8. PubMed ID: 7894000 [TBL] [Abstract][Full Text] [Related]
59. Management of secondary hyperparathyroidism in renal allograft recipients. Wilson RE; Hampers CL; Katz AI; Bernstein DS; Wachman A; Merrill JP; Murray JE Transplant Proc; 1969 Mar; 1(1):206-8. PubMed ID: 4944219 [No Abstract] [Full Text] [Related]
60. Management of hyperphosphatemia in patients with renal failure. Ghazali A; Ben Hamida F; Bouzernidj M; el Esper N; Westeel PF; Fournier A Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):566-79. PubMed ID: 7859019 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]